All Stories

  1. New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC
  2. How to Translate Quality Standards Into Good Lung Cancer Screening Programmes: The UK Experience
  3. Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study
  4. State-of-the-Art Machine Learning Models for Detecting and Mitigating Disparities in Healthcare
  5. Towards Inclusive AI System Development for Disease Risk Prediction: Collecting, Prioritising and Incorporating User Stories from Heterogeneous Stakeholders
  6. Evaluating LIME and SHAP Under Class Imbalance: A Lung Cancer Prediction Case Study Using CPRD Data
  7. Utilization of Lung Cancer Registries in Learning Health Systems for Health Care Improvement
  8. Effective management of incidental findings in lung cancer screening: the role of the screening review meeting
  9. Increasing Lung Screening uptake: Exploring people who smoke and their family members concerns and recommendations regarding screening invitations
  10. Explainable Boosting Machines for Lung Cancer Prediction and Explanation
  11. Decision Tree Models to Select High-Risk Patients for Lung Cancer Screening and Model Interpretability
  12. Achieving earlier diagnosis of symptomatic lung cancer
  13. Quality assurance in lung cancer screening
  14. Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset
  15. The importance of co-located, high intensity smoking cessation support within lung cancer screening: Findings from the Process Evaluation of the Yorkshire Enhanced Stop Smoking study
  16. Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial
  17. Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: an analysis of the rapid cancer registration dataset
  18. Measuring Harms of Lung Cancer Screening
  19. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models
  20. Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD
  21. The Impact of COVID-19 on Lung Cancer Incidence in England
  22. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard
  23. Defining the road map to a UK national lung cancer screening programme
  24. Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals
  25. Lung cancer screening
  26. Lung nodules: sorting the wheat from the chaff
  27. Clinical trials in cancer screening, prevention and early diagnosis (SPED): A systematic mapping review
  28. Important parameters for cost-effective implementation of lung cancer screening
  29. Decision Tree Approaches to Select High Risk Patients for Lung Cancer Screening Based on the UK Primary Care Data
  30. Logistic Regression Approach to a Joint Classification and Feature Selection in Lung Cancer Screening Using CPRD Data
  31. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  32. European Respiratory Society guideline on various aspects of quality in lung cancer care
  33. Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial
  34. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership
  35. Decision Support Tools for Low-Dose CT Lung Cancer Screening
  36. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  37. Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial
  38. Predicting the future risk of lung cancer: development and validation of QCancer2 (10-year risk) lung model and evaluating the model performance of nine prediction models
  39. Acceptability of a standalone written leaflet for the National Health Service for England Targeted Lung Health Check Programme: A concurrent, think‐aloud study
  40. The role of computer-assisted radiographer reporting in lung cancer screening programmes
  41. Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend
  42. Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
  43. Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes audit
  44. Lung Cancer in the United Kingdom
  45. Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks
  46. The Future of Lung Cancer Screening: Current Challenges and Research Priorities
  47. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
  48. Analysis of the baseline performance of five UK lung cancer screening programmes
  49. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
  50. Selection of eligible participants for screening for lung cancer using primary care data
  51. What is the Definition of Cure in Non-small Cell Lung Cancer?
  52. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
  53. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
  54. Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  55. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  56. Factors associated with survival in small cell lung cancer: an analysis of real-world national audit, chemotherapy and radiotherapy data
  57. Participation in lung cancer screening
  58. Importance of research design in biomarkers for lung cancer
  59. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
  60. Selecting Lung Cancer Patients from UK Primary Care Data: A Longitudinal Study of Feature Trends
  61. Reply to Wilson: Improving Lung Cancer Screening Uptake
  62. Pulmonary nodules
  63. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?
  64. An update on CT screening for lung cancer: the first major targeted cancer screening programme
  65. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme
  66. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk
  67. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
  68. Lung Screen Uptake Trial: results from a single lung cancer screening round
  69. Targeted screening for lung cancer is here but who do we target and how?
  70. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection
  71. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort
  72. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe
  73. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials
  74. Lung cancer: investigation and staging
  75. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules
  76. A systematic review of survival following anti-cancer treatment for small cell lung cancer
  77. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England
  78. Correction:Defining the information needs of lung cancer screening participants: a qualitative study
  79. Defining the information needs of lung cancer screening participants: a qualitative study
  80. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening
  81. Evaluation of cardiovascular risk in a lung cancer screening cohort
  82. Ex vivo Raman spectroscopy mapping of lung tissue: label-free molecular characterization of nontumorous and cancerous tissues
  83. Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
  84. Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial
  85. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
  86. Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial
  87. The potential of breath analysis to improve outcome for patients with lung cancer
  88. Status of Lung Cancer Data Collection in Europe
  89. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries
  90. Lung cancer screening – gaining consensus on next steps – proceedings of a closed workshop in the UK
  91. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data
  92. ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe
  93. EUPS—argues that lung cancer screening should be implemented in 18 months
  94. Lung cancer screening—low dose CT for lung cancer screening: recent trial results and next steps
  95. The continuum of screening and early detection, awareness and faster diagnosis of lung cancer
  96. Lung cancer in the UK: addressing geographical inequality and late diagnosis
  97. The Fleischner Society 2017 and British Thoracic Society 2015 guidelines for managing pulmonary nodules: keep calm and carry on
  98. British Thoracic Society quality standards for the investigation and management of pulmonary nodules
  99. Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial
  100. Recent advances in the management of lung cancer
  101. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
  102. Low-dose CT for lung cancer screening – Authors' reply
  103. Low dose CT screening for lung cancer
  104. European position statement on lung cancer screening
  105. Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial
  106. Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?
  107. Use of Volumetry for Lung Nodule Management: Theory and Practice
  108. Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation
  109. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
  110. The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial
  111. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools
  112. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study
  113. Socioeconomic position and delays in lung cancer diagnosis: should we target the more deprived?
  114. What is the Optimum Screening Strategy for the Early Detection of Lung Cancer
  115. Optimum low dose CT screening interval for lung cancer: the answer from NELSON?
  116. Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial
  117. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with periphe...
  118. Implementation planning for lung cancer screening: five major challenges
  119. How should performance in EBUS mediastinal staging in lung cancer be measured?
  120. Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013
  121. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
  122. Defining a standard set of patient-centred outcomes for lung cancer
  123. Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management
  124. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data
  125. Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries
  126. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
  127. Management of pulmonary nodules according to the 2015 British Thoracic Society guidelines. Key messages for clinical practice
  128. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and ‘hard-to-reach’ patients
  129. Lung cancer: investigation and staging
  130. Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules
  131. Pulmonary nodules and CT screening: the past, present and future
  132. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I ...
  133. How should pulmonary nodules be optimally investigated and managed?
  134. CT screening for lung cancer: Is the evidence strong enough?
  135. Integrated Raman microscopy and auto-fluorescence imaging for fast tumour diagnosis during cancer surgery
  136. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
  137. Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  138. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
  139. Development of Guidelines for the Management of Pulmonary Nodules Toward Better Implementation
  140. Correction
  141. Patients’ attitudes to risk in lung cancer surgery: A qualitative study
  142. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators
  143. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial
  144. Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms
  145. Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
  146. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  147. British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE
  148. Screening for lung cancer
  149. Screening
  150. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients
  151. FDG-PET/CT Imaging for Mediastinal Staging in Patients With Potentially Resectable Non–Small Cell Lung Cancer
  152. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial
  153. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit
  154. Author's response: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  155. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer
  156. Next steps and barriers to implementing lung cancer screening with low-dose CT
  157. Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important?
  158. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  159. The impact of the ‘hub and spoke’ model of care for lung cancer and equitable access to surgery
  160. Appetite stimulants for people with cystic fibrosis
  161. The European initiative for quality management in lung cancer care
  162. Lung cancer screening with low dose computed tomography
  163. The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
  164. Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit
  165. Multidisciplinary team management in thoracic oncology: more than just a concept?
  166. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations
  167. Effective lung cancer screening is possible
  168. Treatment decisions and survival for people with small-cell lung cancer
  169. CT screening for lung cancer: countdown to implementation
  170. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
  171. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit
  172. European randomized lung cancer screening trials: Post NLST
  173. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit
  174. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  175. The pathological confirmation rate of lung cancer in England using the NLCA database
  176. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier
  177. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  178. The Association Between Smoking Quantity and Lung Cancer in Men and Women
  179. Authors' response
  180. Measurement Methods and Algorithms for the Management of Solid Nodules
  181. A proposed new imaging pathway for patients with suspected lung cancer
  182. The (US) National Lung Cancer Screening Trial: intensifying the debate about the introduction of screening for lung cancer
  183. What is the Most Effective Follow-up Model for Lung Cancer Patients? A Systematic Review
  184. Lung cancer: investigation and staging
  185. Authors' response
  186. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 Report
  187. Supportive Care in Respiratory Disease
  188. Authors' response
  189. How do patient and hospital features influence outcomes in small-cell lung cancer in England?
  190. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service
  191. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report
  192. Diagnosis and treatment of lung cancer: summary of updated NICE guidance
  193. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA)
  194. Imaging in lung cancer: recent advances in PET-CT and screening
  195. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
  196. Authors' response
  197. Guidelines on the radical management of patients with lung cancer
  198. Diagnosing lung cancer earlier in the UK
  199. Technical validation of an autoantibody test for lung cancer
  200. Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe?
  201. Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes
  202. Lung cancer: investigation and staging
  203. Appetite stimulants in cystic fibrosis: a systematic review
  204. BTS statement on malignant mesothelioma in the UK, 2007
  205. NICE guidance for screening for malnutrition: implications for lung cancer services
  206. Lung cancer outcomes at a UK cancer unit between 1998–2001
  207. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
  208. Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine
  209. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy
  210. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2
  211. Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions?
  212. Questionnaire survey of male infertility in cystic fibrosis
  213. Development of an expert system for the interpretation of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Midlands Thoracic Society Research Group.
  214. How Do General Practitioners Respond to Reports of Abnormal Chest X-rays?
  215. Comparison of two new methods for the measurement of lung volumes with two standard methods
  216. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
  217. Comparative clinical and physiological features of Maori, Pacific Islanders and Europeans with sleep related breathing disorders
  218. Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea
  219. Pragmatics: Principals of Design and Evaluation of an Information System for a Department of Respiratory Medicine
  220. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease
  221. Silicosis presenting as bilateral hilar lymphadenopathy.
  222. SHORT COMMUNICATION: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers
  223. Effect of diuretics on allergen-induced contractions of passively sensitized human bronchi in vitro.
  224. Nocturnal oxygen desaturation and exercise-induced desaturation in subjects with chronic obstructive pulmonary disease
  225. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose
  226. Scoring system developed for drug related morbidity
  227. Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.
  228. The concentration of sparfloxacin in lung tissues after single and multiple oral doses
  229. The levels of clarithromycin and its 14-hydroxy metabolite in the lung
  230. Cross refractoriness between sodium metabisulphite and exercise induced asthma.
  231. Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosis
  232. The Effect of Sodium Transport and Calcium Channel Inhibitors on Phorbol Ester-induced Contraction of Bovine Airway Smooth Muscle
  233. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration
  234. Laparoscopic cholecystectomy in patients with cystic fibrosis
  235. Quantitative morphology and water distribution of bronchial biopsy samples.
  236. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.
  237. Pulmonary disposition of antimicrobial agents: methodological considerations.
  238. Bronchoalveolar distribution of cefaroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens
  239. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies
  240. The site concentrations of antimicrobial agents in the lung
  241. Microlavage: a technique for determining the volume of epithelial lining fluid.
  242. Comparative pharmacokinetic disposition of fluoroquinolones in the lung
  243. In-vitro activity and β-lactamase stability of SR 44337, a new long acting cephalosporin
  244. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics
  245. The penetration of cefpirome into the potential sites of pulmonary infection
  246. Concentrations of oral lomefloxacin in serum and bronchial mucosa.
  247. Concentrations of temafloxacin in serum and bronchial mucosa
  248. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.
  249. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose